LVTX News and Press, LAVA Therapeutics N.V. From 06/08/23

Lead development candidate selected by Janssen Biotech under research collaboration provides a milestone payment to LAVA Strong balance sheet expected to provide cash runway into 2026 UTRECHT, The Netherlands and PHILADELPHIA, June 08, 2023 (GLOBE NEWSWIRE) -- LAVA Thera...

2023-06-06 08:37:27 ET Brera Holdings ( BREA ) +104% Acquires Strategic Stake in Manchester United PLC. Hoth Therapeutics ( HOTH ) +24% Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease. GitLab ( GTLB ) +27% Q1 earnings ca...

2023-06-02 13:27:06 ET Gainers: LAVA Therapeutics N.V. ( LVTX ) +79% . U Power Limited ( UCAR ) +34% . Samsara ( IOT ) +30% . MongoDB ( MDB ) +27% . Digital Ally ( DGLY ) +26% . iHeartMedia ( IHRT ) +24% . The Che...

2023-06-02 10:02:23 ET Gainers: Connect Biopharma ( CNTB ) +26% . LAVA Therapeutics ( LVTX ) +19% . Panbela Therapeutics ( PBLA ) +18% . Apollomics ( APLM ) +15% .  Rockwell Medical ( RMTI ) +10% . Losers: Kiora Pharm...

2023-06-01 17:29:40 ET Gainers: LAVA Therapeutics  ( LVTX ) +24% . MongoDB ( MDB ) +23% . lululemon athletica  ( LULU ) +13% . Stratasys ( SSYS ) +7% . Everbridge ( EVBG ) +6% . Losers: Braze ( BRZE ) -5% ...

Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies. In May 2020, LAVA entered into a research collaboration and license agreement with Janssen for the discovery and development of novel bispecific antibody-base...

UTRECHT, The Netherlands and PHILADELPHIA, June 01, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ), an immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers to transform the ...

UTRECHT, The Netherlands and PHILADELPHIA, May 30, 2023 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. ( Nasdaq: LVTX ) (LAVA), a clinical-stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma-delta T cell engagers, today announced ...

2023-04-11 07:32:24 ET LAVA Therapeutics press release ( NASDAQ: LVTX ): Q4 GAAP EPS of -$0.57. Revenue of $2.64M (+146.7% Y/Y). For further details see: LAVA Therapeutics GAAP EPS of -$0.57, revenue of $2.64M

Initial clinical data for LAVA-051 suggest a favorable safety profile and initial anti-tumor activity in the ongoing dose escalation Phase 1/2a clinical trial in patients with relapsed and refractory chronic lymphocytic leukemia and multiple myeloma Initial clinical data for LAVA-1207, a ...